Compare Tempus AI (TEM) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs Thomson Reuters Corp — how do they compare? Tempus AI trades at $49.03 (market cap $8.69B), while Thomson Reuters Corp trades at $95.72 (market cap $41.28B). The key difference: Thomson Reuters Corp is far larger — about 4.8× Tempus AI's market cap, and Thomson Reuters Corp pays a 2.75% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| TEM | TRI | |
|---|---|---|
Market Cap | $8.69B | $41.28B |
Sector | Broad Market / Factor | Industrials |
52-Week High | $103.25 | $205.54 |
52-Week Low | $42.37 | $76.55 |
Enterprise Value | $9.37B | $43.24B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $48.41, down 7.74% in the last 24 hours, reflecting a bearish technical signal. The company reported revenue of $1.27 billion in 2025 but a net loss of $245.03 million, with negative profitability metrics. Recent news highlights growth in AI-driven diagnostics and data services, including FDA approvals and research collaborations. The stock is trading well below the analyst consensus price target of $68.50, with a majority of analysts maintaining a Buy rating.
The outlook for TEM is a mix of high growth potential in healthcare AI and significant financial risk due to persistent losses. Investment opportunity lies in its proprietary data platform and expanding market reach, but risks include execution challenges and cash burn. Wall Street sentiment remains positive on long-term prospects, but investors should weigh the volatility against the company's unproven path to profitability.
Thomson Reuters (TRI) trades at $95.43, down 0.8% today, with a bullish technical signal and strong analyst consensus. The stock shows robust profitability with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent corporate actions include a special dividend and a reverse stock split, while news highlights AI integration and a joint venture with KKR.
Outlook is positive with a consensus price target of $129.96 implying 36% upside, supported by solid cash flow and debt reduction. Risks include execution of AI strategy and competitive pressures. Wall Street sentiment is bullish with 52% buy ratings, but investors should monitor Q2 2026 earnings due August 5 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
